DexCom — Jan 7, 2026 release

For fiscal 2025, total preliminary, unaudited revenue is approximately $4.662 billion, an increase of 16% over 2024. In conjunction with the preliminary fourth quarter results, the company is also reiterating 2025 non-GAAP gross profit margin guidance of approximately 61% and non-GAAP operating margin guidance of 20-21%. “We are pleased to finish 2025 on a strong note with revenue exceeding the high end of our guidance and the initial launch of our latest sensor technology with the G7 15 Day system,” said Jake Leach, Dexcom’s president and CEO. “With clinical momentum building across the CGM category, we look forward to extending our growth runway through continued innovation and evidence generation in 2026.” 2026 Outlook For 2026, Dexcom currently anticipates total revenue of $5.16 - $5.25 billion, representing expected growth of approximately 11-13% over 2025. This outlook considers sensor volume growth driven by increasing CGM awareness for people with diabetes, the continued rollout of Stelo, further international expansion, and overall market dynamics. In addition, Dexcom currently estimates 2026 Non-GAAP Gross Profit Margin and Non-GAAP Operating Margin to be at the following levels: – Non-GAAP Gross Profit Margin of approximately 63 – 64% – Non-GAAP Operating Margin of approximately 22 – 23% Fourth Quarter 2025 Financial Results Conference Call Dexcom will report its audited full fourth quarter and fiscal 2025 financial results on Thursday, February 12, 2026 after the close of market. Mana